Citius oncology books first sales as LYMPHIR commercial launch gains traction
Share
Citius Oncology (NASDAQ:CTOR) officially transitioned from a development-stage clinical trial outfit to a revenue-generating commercial entity this quarter, posting its first sales of the newly approved immunotherapy LYMPHIR.
